The hyperactivation of the PI3K/Akt/mTOR pathway was reported also in B-ALL, where encouraging results have been obtained with the inhibitors of PI3K/mTOR and MEK1/2 [108]. This evidence concerns the gene AKT1 and acute lymphoblastic leukemia.